[The multicenter study on the registration and follow-up of low anticoagulation therapy for the heart valve operation in China].
OBJECTIVE
To investigate the optimal anticoagulation methods and monitoring strategy for Chinese patients undergoing heart valve replacement, which is potentially quite different from western populations.


METHODS
In this multicenter prospective cohort study, the anticoagulation and monitoring strategy data was acquired from 25 773 in-hospital patients in 35 medical centers and 20 519 patients in outpatient clinic in 11 medical centers from January 1st, 2011 to December 31th, 2015.


RESULTS
As for in-hospital patients, mean age of study population was (48.6±11.2) years old; main etiology of valve pathology was rheumatic (87.5%) origin among study cohort; 94.8% of study population received mechanical valve implantation; international normalized ratio (INR) monitoring (in all the study centers) and low-intensity anticoagulation strategy (31 hospitals chose target INR range of 1.5-2.5, and actual values of INR among 89.2% of 100 069 in-hospital monitoring samples were 1.5-2.5), with mean actual INR values of 1.84±0.53, and warfarin dosage of (2.82±0.93) mg/d were widely adopted among the study centers; strategies of in-hospital warfarin administration were similar in all the study centers; complication rates of low-intensity anticoagulation strategy were low in severe hemorrhage (0.02%), thrombosis (0.05%), and thromboembolism (0.05%) events, without anticoagulation-related death.As for 18 974 outpatient clinic patients, the follow-up rate was 92.47%, with a total of 30 012 patient-years (Pty). Anticoagulation-related morbidity and mortality rates were 0.67% and 0.15% Pty; major hemorrhage morbidity and mortality rates were 0.25% and 0.13% Pty; thromboembolism morbidity and mortality rates were 0.45% and 0.03% Pty.The mean dosage of warfarin daily dosage was (2.85±1.23) mg/d and INR value was 1.82±0.57.No significant regional difference in the intensity of anticoagulation therapy was noted during the study.


CONCLUSIONS
INR can be used as a normalized indicator for intensity of anticoagulation therapy in China.The optimal anticoagulation intensity with INR range from 1.5 to 2.5 is safe and effective for Chinese patients with heart valve replacement, and there is no significant regional difference in the intensity of anticoagulation therapy.
Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
L
L
Dong
Y K
YK
Shi
J P
JP
Xu
E Y
EY
Zhang
J C
JC
Liu
Y X
YX
Li
Y M
YM
Ni
Q
Q
Yang
T
T
Han
B
B
Fu
J
J
Chen
L
L
Ren
S L
SL
Wei
H
H
Chen
K X
KX
Liu
F X
FX
Yu
J S
JS
Liu
M D
MD
Xiao
S M
SM
Wu
K L
KL
Zhang
H L
HL
Huang
S L
SL
Jiang
C H
CH
Qiao
C S
CS
Wang
Z Y
ZY
Xu
X M
XM
Zhou
D J
DJ
Wang
L X
LX
Ni
Y B
YB
Xiao
S L
SL
Jiang
G M
GM
Zhang
G Y
GY
Liang
S Y
SY
Yang
P
P
Bo
Q J
QJ
Zhong
J B
JB
Zhang
X
X
Zhang
Y B
YB
Zhu
X
X
Teng
P
P
Zhu
F
F
Huang
Y M
YM
Xiao
G Q
GQ
Cao
H
H
Tian
L M
LM
Xia
F L
FL
Lu
Y Q
YQ
Liu
D X
DX
Liu
H
H
Xu
Y
Y
Yuan
M
M
Li
C
C
Chang
X C
XC
Wu
Z
Z
Xu
P
P
Guo
Y J
YJ
Bai
W B
WB
Xue
X Y
XY
Jiang
Z H
ZH
Na
Q Y
QY
Zeng
H
H
Cai
Y L
YL
Wang
R
R
Xiong
S
S
Jin
X M
XM
Zheng
D
D
Wu
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D044466:Asian People; D001777:Blood Coagulation / Q000187:drug effects*; D002681:China / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation; D006470:Hemorrhage / Q000401:mortality; D006801:Humans; D019934:International Normalized Ratio; D008875:Middle Aged; D009017:Morbidity; D011183:Postoperative Complications / Q000401:mortality; D011446:Prospective Studies; D013923:Thromboembolism / Q000401:mortality; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use*
D000925:Anticoagulants; D014859:Warfarin